Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

BACKGROUND: PI3K–AKT–mTOR inhibitors (PAMi) are promising anticancer treatments. Hyperglycaemia is a mechanism-based toxicity of these agents and is becoming increasingly important with their use in larger numbers of patients. METHODS: Retrospective case-control study comparing incidence and severit...

Descripción completa

Detalles Bibliográficos
Autores principales: Geuna, E, Roda, D, Rafii, S, Jimenez, B, Capelan, M, Rihawi, K, Montemurro, F, Yap, T A, Kaye, S B, De Bono, J S, Molife, L R, Banerji, U
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705886/
https://www.ncbi.nlm.nih.gov/pubmed/26554652
http://dx.doi.org/10.1038/bjc.2015.373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705886/
https://www.ncbi.nlm.nih.gov/pubmed/26554652
http://dx.doi.org/10.1038/bjc.2015.373

Ejemplares similares